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ABSTRACT
The parasitic protozoa Giardia intestinalis and Entamoeba histolytica are major
health concerns and responsible for hundreds of millions of cases of intestinal disease per
year. Strains of both parasites have been discovered that show resistance to
metronidazole, the most prevalent treatment for these pathogens. Thus, there is a need to
identify new drugs and drug targets to combat the growing threat of drug resistant
parasites. The parasite enzyme methylthioadenosine nucleosidase (MTN) is one such
potential target. Traditional drug development processes take almost a decade and
hundreds of millions of dollars to complete. In an effort to shorten that timeline and
reduce development costs, the drugs tested in this study were found by in silico screening
of a drug library containing thousands of small molecules to identify a subset of
compounds that showed theoretical high binding affinities to the E. coli MTN enzyme.
Enzymatic screening of the 33 tightest binding drugs yielded four potent inhibitors of E.
coli MTN that also showed inhibitory activity against target parasite MTNs. The
inhibition profiles of these drugs against parasite MTNs and the human enzyme
methylthioadenosine phosphorylase (MTAP) were extensively characterized. The drugs
were also tested against live cell cultures of Giardia intestinalis and human cell lines for
growth inhibitory activity. The drug 5A (N-(2-furyl methyl)-N'-(4-nitrophenyl)urea)
showed an IC50 of 10.8 µM against Giardia intestinalis cultures, while exhibiting an IC50
of over 100 µM against human cells. These results suggest that the MTN inhibitors
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identified in this work are potential lead compounds for further development, and that in
silico drug screening is an effective strategy for identifying anti-parasitic agents.
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CHAPTER ONE: INTRODUCTION
Parasites
The word parasite comes from the Greek, parasitos, which means “beside food”
and was the name used for servers at feasts. The word evolved to describe sycophants
who hung around banquets for table scraps. In science, the definition has evolved to
describe any organism that survives by taking nutrients from a host that suffers from the
arrangement. Certain bacteria and viruses could equally fit this definition but they are
classified separately for historical reasons (Zimmer, 2000).
Parasites that live inside a host (endoparasites) include protozoa (e.g., Giardia
intestinalis, Entamoeba histolytica), digeneans (e.g., Schistosoma mansoni), cestodes
(e.g., Taenia solium), nematodes (e.g., Trichinella spiralis), and acanthocephalans (e.g.,
Moniliformis clarkia). Parasites that live outside the host (ectoparasites) include
arthropods (e.g., Ixodes tick) and most monogeneans (e.g., Diplozoon paradoxum) (Bush,
Fernandez, Esch, & Seed, 2001). It is thought that most parasites started out as free-living
creatures that evolved in order to survive on or inside other living things. This evolution
is proposed to have proceeded in a stepwise manner, where the initial requirement was
parasite-host interaction that included some form of pre-adaptation to the host
environment to allow full time occupancy of host tissues. It was also an evolutionary
imperative that the parasites have a better chance of survival while associated with the
host than they would as free-living creatures (Poulin, 2007).
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Anthropologists have proposed that approximately half the humans who have ever
lived, likely died from some form of parasitic infection (Drisdelle, 2010). This assertion,
though impossible to prove, may be true. Parasites are the largest category of infectious
diseases. They have evolved mechanisms that allow them to survive varying conditions
inside and outside the host, and can be found infecting all known species of higher
organisms (Roberts & Janovy, 2013).
Parasitic illnesses are often considered “diseases of poverty.” This is an over
simplification of the real impact of parasitic infection. According to the Oxford Poverty
and Human Development Initiative’s Multidimensional Poverty Index, approximately 1.6
billion of the 7 billion people inhabiting the planet are living in abject poverty (Alkire &
Seth, 2013). The World Health Organization considers infectious disease a large
contributing factor to poverty. Lifting the burden of infectious disease would
automatically improve the over-all economic future of humanity. Proof of this principle
can be seen in the economic advantages resulting from the near eradication of
dracunculiasis or guinea worm disease. Inexpensive water filters, community outreach,
and education programs have allowed millions of people who were formerly at risk of
losing months of income while afflicted with the worm to work, go to school, and
otherwise improve their chances of economic stability (Cairncross, Müller, & Zagaria,
2002).
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Table 1.
Parasite
Scientific
Name
Giardia
intestinalis
Toxoplasma
gondii
Trichomonas
vaginalis
Entamoeba
histolytica
Plasmodium
spp.
Schistosoma
mansoni
Trypanosoma
spp.

World Wide Prevalence of Parasitic Infections
Parasite
Common Name

Estimated
World
Prevalence
2-3 billion

Estimated
Mortality Rank

Relative U.S.
Prevalence

Low

Toxoplasmosis

1-2.5 billion

Very low

1-2 million per
year
Low

Trichomoniasis

15% of women

Very low

Giardiasis
“beaver fever”

Amebiasis

200-400
million
Malaria
200-300
million
Schistosomiasis 200-300
million
Chagas disease 15-20 million
“African Sleeping
sickness”

No. 2

Considered a
common STD
Low

No. 1

Low

No. 3*

Uncommon

No. 3*

Increasing in
U.S.

Leishmaniasis
12 million
No. 3*
Large concern
Leishmania
of U.S. military
spp.
Adapted from Thom & When, 2012. * tie ranking due to a lack of accurate data.

The mortality and morbidity due to parasitic diseases are enormous (Table 1).
Worse, parasites are incredibly difficult to kill without causing harm to their host, since
they share so much in common with the host at the cellular and metabolic level. Thus,
there are relatively few anti-parasitic drugs available, and most of them have some degree
of toxicity to humans, particularly with repeated or prolonged use. For example, malaria,
which causes the most deaths annually of any of the parasites, has approximately eight
different commonly used treatments. Most of these anti-malarials have toxicities that
limit their use in young children or pregnant women. Unfortunately, these are the same
patient populations that are most likely to suffer severe forms of the disease and are at the
highest risk of death from malaria (CDC, 2013). Despite issues of drug toxicity, a
measure of pseudo-control over parasitic infections has been achieved with the help of
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environmental management to reduce vector transmission, and the use of anti-parasitic
agents. Unfortunately, this has resulted in selective pressures that have pushed both
arthropod vectors and parasites to adapt and evolve drug resistance. Isolates of drug
resistant parasites have been reported for virtually every anti-parasitic therapeutic in
current use (Poulin, 2007). Much like bacteria, parasites employ many mechanisms to
develop drug resistance, including genetic mutations that result in insensitive or
overexpressed target enzymes and proteins, altered metabolism, expression of drug efflux
pumps, and epigenetic changes (Sharma et al., 2013).
Whatever the mechanism, the result is the same. Drugs that were extremely time
consuming and expensive to produce are now ineffective in treating certain strains of
parasites. Alexander Fleming, the discoverer of penicillin, argued in 1946 that
chemotherapeutic drugs capable of sustained activity against microbes were unlikely due
to their inherent ability to mutate rapidly and acquire resistance (Fleming, 1946;
Alekshun & Levy, 2007). Thus, there is a continual need to rapidly and cheaply identify
new antibiotics. Recent research has begun to explore the development of antibiotics that
modulate pathogen growth and virulence, without creating a strong selective pressure for
drug resistance that typically accompanies cytotoxic drugs. This, along with drug
rotation, combination drug therapy, and appropriate antibiotic use should result in longer
periods of drug effectiveness (Davies & Davies, 2010).
Giardia intestinalis
Giardia intestinalis (sometimes referred to as G. duodenalis or G. lamblia) is a
parasite of the phylum Protozoa, order Diplomonadida. As seen in Figure 1, Giardia
intestinalis exists as a motile single-celled trophozoite inside the host intestinal tract. The
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trophozoite has a 12-15 µm long dorso-ventrally flattened body that is convex on the
dorsal surface. The dorsal surface also contains a bi-lobed adhesive disc used to attach to
the surface of host cells lining the intestinal wall. Giardia is unusual in that it contains
two nuclei behind the lobes of the adhesive disks, thus conferring tetraploidy and giving
the trophozoite its distinctive “bespectacled” look when viewed under the microscope.
Giardia lacks other organelles such as Golgi bodies, lysozomes, and smooth endoplasmic
reticulum, but does develop four pairs of flagella that allow rapid movement when
unattached from the intestinal wall. Giardia is also amitochondriate and lacks respiratory
metabolism. Instead it relies on anaerobic fermentation and salvage of host nutrients to
supply its metabolic needs (Roberts & Janovy, 2013).
Giardia infections begin by ingestion of heavily walled parasite cysts. Once in a
new host, stomach acid and digestive enzymes begin to degrade the parasite cyst wall. In
the duodenum, the organism completes excystation and two new flagellated trophozoites
emerge to establish an infection in the duodenum and jejunum. The trophozoites attach
to the intestinal mucosal lining through the ventral adhesive disks and absorb nutrients
from intestinal cell exudates and luminal contents. The infection proceeds as the
trophozoites replicate by binary fission. Unattached trophozoites migrate to the drier stool
of the colon where they encyst in a process that envelopes the trophozoite in protective
fibers. The hardened cysts are then excreted by the host and transmitted to the next host
through fecal contamination of food or water (Roberts & Janovy, 2013).
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Figure 1.

Giardia intestinalis Life Cycle (CDC, 2014 a).

Because Giardia attaches to the lining of the small intestine in the host, the most
common symptoms of infection are chronic diarrhea, greasy stool, foul smelling
flatulence, intestinal cramping, rectal fissures, and weight loss (Ali & Hill, 2003). In
healthy adults with robust immune systems the infection may be asymptomatic. This can
lead to unknowing transmission of the disease to close contacts (Thompson, 2000).
Giardia is rarely fatal but severe disease does occur. In most cases of severe disease, the
victims are commonly immune-compromised individuals, children under age 5, or
pregnant women (Teunis, Medema, Schets, & Havelaar, 1998). Since Giardia is the
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leading cause of reported outbreaks of waterborne illness in the United States, it remains
a significant widespread health hazard (Lengerich, Addiss, & Juranek, 1994).
According to recent CDC estimates, the annual incidence of giardiasis was
estimated at > 1.2 million cases in the United States alone (Scallan et al., 2011).
Worldwide infection rates are estimated at over a billion cases annually (Auerbach,
2007). Even in places where water quality is heavily regulated, outbreaks still occur due
to the extreme toughness of the cysts, which resist killing by chlorination and UV
irradiation (Isaac-Renton, Cordeiro, Sarafis, & Shahriari, 1993). True preventative
measures require filtration mechanisms that can exclude particles larger than 10 µm. In
some instances, even these precautions fail to fully decontaminate water supplies
(LeChevallier, Norton, & Lee, 1991a, b).
The primary treatment for giardiasis is the nitroimidazole drug metronidazole.
The standard daily oral dose for treatment of giardiasis is 500 to 750 mg for five to ten
days (National Toxicology Program, 2011). Metronidazole is believed to be a human
carcinogen because experiments in rats and mice have shown that oral treatment with
metronidazole increases rates of tumor formation (National Toxicology Program, 2011).
Other treatments such as albendazole and tinidazole are also used, but have been reported
to be either mutagenic or teratogenic (Abboud et al., 2001; Karabay et al., 2004).
Considering that the most common sufferers of giardiasis are young children and
pregnant women, these side effects are unacceptable. For this reason, along with the
emergence of metronidazole resistant isolates of Giardia intestinalis and the common
recurrence of disease in previously treated patients, the need for a new drug treatment
regimen is at an all-time high.
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Entamoeba histolytica
Entamoeba histolytica is a parasite of the phylum Protozoa, order Lobosea.
Inside the host gastrointestinal tract, E. histolytica exists as a 10-60 µm long trophozoite
with short, blunt pseudopodia for locomotion. Like Giardia, E. histolytica cells are
amitochondriate and lack respiratory metabolism. The cytoplasmic membranes are quite
thin and clear, which allows for visualization of the nucleus and endosomes after
staining. Food vacuoles often contain host erythrocytes, which are darker than the
surrounding endoplasm and make the cells look like chocolate chip cookies (Figure 2).

Figure 2.

Entamoeba histolytica Life Cycle (CDC, 2014 b).
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Similar to Giardia, infection by Entamoeba begins with ingestion of cysts. The
major source of infectious cysts is fecal contaminated food and drinking water. Other
sources include anal sex and overcrowded, unhygienic living conditions (Walsh, 1986).
Inside the host, E. histolytica excyst to form trophozoites that colonize the large intestine.
Trophozoites divide by rapid binary fission into four daughter trophozoite cells. In
asymptomatic patients, some trophozoites migrate to the drier stool of the colon where
encystations occurs. Cysts are subsequently shed in the stool.
If untreated, Entamoeba histolytica causes amoebiasis. The most common
symptoms of infection are chronic bloody diarrhea, cramps, and vomiting (Roberts &
Janovy, 2013). Asymptomatic disease is common. The parasite can invade the tissues of
the cecum, leading to tissue ulceration and migration via the blood stream to other host
organs (mainly liver, lung, and brain), where it can further invade to cause potentially
fatal abscesses and tissue necrosis (Roberts & Janovy, 2013).
Amoebiasis can also be fatal when the host suffers acute dysentery leading to
extreme dehydration. The victim is usually an otherwise healthy young man who delays
seeking treatment until the symptoms become unbearable. In other cases of death, the
victims are usually the very young, the very old, or the immunocompromised. In total,
approximately 50-100,000 people die every year from amoebiasis, which makes it second
only to malaria as the leading cause of death due to parasites (Stanley, 2003).
Like giardiasis, metronidazole is the most common treatment for amoebiasis. The
standard oral dose for treatment of amoebiasis is only slightly lower than the dose that
has been shown to cause tumors in mice and rats (Roberts & Janovy, 2013). Increasing
reports of metronidazole treatment failure suggest drug resistance has begun to develop in
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E. histolytica (Bansal, Malla, & Mahajan, 2006). Albendazole has been used effectively
to treat metronidazole resistant amoebiasis. However, albendazole is a known teratogen
and is contra-indicated in the treatment of amoebiasis in pregnant women (Venkatesan,
1998; Abboud et al., 2001; Karabay et al., 2004). A vaccine against amoebiasis has been
tested in animals, but has yet to be approved for use in humans (Stanley, 2006).
Unfortunately, the lack of sustained immunity following native infection suggests that the
development of a successful vaccine will be difficult (Haque et al., 2006), and further
supports the need to develop additional therapeutics to treat amoebiasis.
Methionine, SAM Reactions, and the Methionine Salvage Pathway
Methionine is an extremely important amino acid for all cells due to its role in a variety
of biochemical reactions including protein synthesis, the synthesis of other amino acids
through trans-sulfuration reactions, and the creation of S-adenosylmethionine (Nozaki,
Ali, & Tokoro, 2005). Parasites (like humans) do not make sufficient methionine to meet
their metabolic needs, thus it is termed an “essential” amino acid (Huxtable, 1986). In
parasites, widespread methionine auxotrophy sponsors both methionine scavenging
systems from the host, as well as salvage pathways to recycle the sulfur containing amino
acid (Marr & Müller, 1995).
The majority of methionine is used to create S-adenosylmethionine (SAM,
AdoMet) from ATP using the enzyme methionine-adenosyl transferase (MAT, or SAM
synthase) (Figure 3). SAM is an activated nucleoside that is a source of chemical groups
used in hundreds of biochemical reactions, including methylation reactions, polyamine
synthesis, and radical SAM reactions (Fontecave, Atta, & Mulliez, 2004). Byproducts of
these reactions consist of adenine nucleosides from which salvage of both the methionyl
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sulfur and purine base are important due to the underlying auxotrophy for these
compounds in the protozoan parasites like G. intestinalis and E. histolytica.

Figure 3.
SAM Synthesis. Methionine adenosyl transferase (MAT)
catalyzes the addition of methionine to ATP to make SAM, pyrophosphate,
and orthophosphate.

The primary role of SAM is to serve as a methyl group donor in a wide array of
transmethylation reactions used to modify cellular DNA, proteins, and other small
molecules (Figure 4). S-Adenosylhomocysteine (SAH, AdoHcy) is produced as a
byproduct of the reaction (Chiang et al., 1996; Fontecave et al., 2004; Grillo &
Colombatto, 2005). Transmethylation reactions play a critical role in a variety of cellular
processes including the regulation of gene expression, proper assembly of membrane
constituents, and protein-protein interactions. SAH is a product inhibitor of
transmethylation reactions, and is catabolized efficiently to prevent intracellular
accumulation (Kloor & Oswald, 2004; Hall & Ho, 2006). Two enzymes are of major
interest for interruption of methionine salvage and SAM recycling in target organisms:
SAH hydrolase (SAHH) and MTA nucleosidase (MTN).

12

Figure 4.
The Methionine Salvage Cycle. Three main pathways exist to
recycle methionine and adenine byproducts of SAM reactions. Variation
exists in the pathways depending on the parasite. However, both Entamoeba
and Giardia contain active MTN enzymes.
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SAM reactions are crucial for parasite replication and thus inhibition of SAM
production or recycling would result in stunted growth, making enzymes related to SAM
pathways attractive targets for drug development (Parker et al., 2003). SAHH catabolizes
S-adenosylhomocysteine (SAH). SAHH inhibition would cause intracellular SAH
accumulation, in turn leading to feedback inhibition of methylation reactions (Figure 5).
Inhibition of methylation reactions would impair DNA replication and can trigger
apoptosis (Parker et al., 2003; Gopisetty, Ramachandran, & Singal, 2005). Thus, SAHH
inhibition is a tempting target for new drug development. Indeed, some success has been
found with carbocyclic 3-deazaadenosine, an SAHH inhibitor that has shown promise as
an antiviral drug against Ebola infections in mice (Huggins, Zhang, & Bray, 1999).
Unfortunately, the SAHH enzymes present in both humans and parasites bear a striking
structural homology, which would make the selective targeting of parasite SAHH
extremely difficult. Thus far, no inhibitors of parasite SAHH have been found that could
act as broad spectrum anti-parasitic drugs while leaving the human SAHH unaffected
(Parker et al., 2003; Minotto, Ko, Edwards, & Bagnara, 1998).

Figure 5.
Methyltransferase Reactions. SAM is the most common methyl
donor in methylation reactions. SAH is a product inhibitor of these reactions.
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Methylthioadenosine Nucleosidase (MTN): A New Drug Target
In plants and many microbes, the enzyme methylthioadenosine nucleosidase
(MTN) catabolizes MTA to MTR and adenine (Figure 4). MTA is the product of
polyamine synthesis (spermidine, spermine) that utilizes decarboxylated SAM as a
propylamine donor (Figure 6). Polyamines are important for DNA replication and cell
proliferation. MTA is a potent product inhibitor of polyamine synthesis, and is cytotoxic
when it accumulates in the cell. Since MTN is not found in mammalian cells, it is a
possible target for chemotherapeutic agents (Riscoe, Ferro, & Fitchen, 1989; Walker &
Barrett, 1997). Instead, mammals have MTA phosphorylase (MTAP), which works on
the same substrate but has different enzymatic binding properties that may be exploitable
for development of selective MTN-specific antibiotics (Lee et al., 2004).

Figure 6.
Polyamine Synthesis. Spermidine synthase catalyzes the
propylamine transfer from dcSAM to putrescine to form spermidine and MTA.
MTA is a potent product inhibitor of polyamine synthases. G. intestinalis and
E. histolytica lack both SAM decarboxylase (SAMdc) and spermidine synthase
(Spds) in their genomes, and salvage polyamines and MTA from the host
(Reguera, Redondo, Pérez-Pertejo, & Balaña-Fouce, 2007).

One other pathway of note involves the use of SAM as an oxidizing agent in
radical reactions. The radical SAM enzymes reduce the sulfonium on SAM via a
coordinated iron-sulfur cluster (Jarrett, 2003; Challand et al., 2009) to create methionine
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and 5’-deoxyadenosine (5’-dADO) radical, which then abstracts hydrogen from any
nearby substrate with a C-H bond (Figure 7) (Igarashi & Kashiwagi, 2010). The
substrates vary and usually result in anaerobic oxidations, sulfur insertions,
isomerizations, ring formations, and other unusual methylations (Jarrett, 2003; Parveen &
Cornell, 2011). Members of the radical SAM superfamily of enzymes, including biotin
synthase, lipoyl synthase, and tyrosine synthase, were all product inhibited by 5’-dADO
and methionine (Challand et al., 2009). The activity of SAM superfamily enzymes was
restored when MTN was added to the assays. Thus, inhibition of MTN that catabolizes
5’dADO to adenine and 5-deoxyribose is likely to ultimately lead to product inhibition of
these radical SAM enzymes. This could lead to depletion of the biotin, lipoate, and
thiamine cofactors required for numerous metabolic enzymes in the cell, and impairment
of central carbon metabolism (Parveen & Cornell, 2011). There are about forty known
radical SAM reactions that are necessary for the cell (Jarrett, 2005; Frey, Hegeman, &
Ruzicka, 2008). While it is not known if product inhibition is universal, the fact that it
occurs in some radical SAM reactions makes MTN an even better drug target.

Figure 7.
Radical SAM Reactions. SAM is used in radical reactions that
are important in pathways that produce vitamins such as biotin, lipoate, and
thiamine.
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The methionine salvage pathways of the parasitic protozoa studied here are more
complicated than the general bacterial pathway. Analysis of the publically available
Giardia intestinalis genomes reveals the presence of two MTN genes, but not SAHH
genes. This is contrary to a previous report that Giardia intestinalis contained a
standalone SAHH (Riscoe et al., 1989). Thus the Giardia MTNs should act like bacterial
MTNs and catabolize all three nucleosides: MTA, SAH, and 5’-dADO. This suggests
that MTN inhibition will target methionine and purine salvage from three substrates:
SAH, MTA, and 5’-dADO. In contrast to Giardia, the Entamoeba histolytica genome
contains the genes for SAHH and MTN, and thus catabolizes SAH to adenosine and
homocysteine, while only MTA and 5’dAdo are degraded by MTN.
Genomic analysis also reveals that Giardia and Entamoeba lack SAM
decarboxylase and spermidine synthase, but instead have a separate polyamine synthetic
pathway that may be specific to anaerobic protozoan parasites. In this alternate pathway,
arginine is converted by arginine deiminase (ARGd) to citrulline that is then converted by
ornithine carbomyl transferase (OCT) to ornithine, which is then converted by ornithine
decarboxylase (Odc) to putrescine (Figure 8). Indeed, in these parasites putrescene is the
predominant polyamine, while spermidine and spermine are in low concentration and
probably originate from the host (Marr & Müller, 1995; Reguera, Tekwani, & BalañaFouce, 2005). This revelation raises the question as to the source of MTA within the
parasites, since they appear to lack SAM decarboxylase and spermidine synthase. It
would appear that the answer may be found in the presence of a MTA P2 transporter in
parasites that is capable of transporting MTA from the host (Goldberg, Rattendi, Lloyd,
Sufrin, & Bacchi, 2001).
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Figure 8.
Alternative Polyamine Synthesis Pathway for Putrescine.
The pathway for production of putrescine in Giardia intestinalis and
Entamoeba histolytica is based upon genomic data.

These deviations from the prototypical polyamine pathway are not unexpected.
After all, protozoa are a very large and disparate group of organisms with at least 500
million years of divergent evolution in metabolic pathways to accommodate differences
in host, life cycle, and location of colonization. As such, it is imperative that present
studies focus on the constructed genomes of each organism to gain a full understanding
of which enzymes are present in order to identify better drug targets within those
pathways that will lead to the development of better drugs.
Inspection of the parasite genomes in this study revealed that MTN is an essential
enzyme for purine salvage. Alignments of E. coli and parasite MTN primary sequence
(Figure 9) show that the active site residues in the MTN enzymes are highly conserved.
A greater than 68% homology was found between all the target MTN enzymes, while
significant homology was not found with the human MTAP enzyme. This suggests that
it could be possible to develop drugs that would work as broad spectrum antibiotics by
inhibiting MTNs in both parasites, but not cross react with human MTAP.
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EC
GI MTN-1
GI MTN-2
EH
MTAP

-----------MKIGIIGAMEEEVTLLRDKIEN
MLVSKEARRTAPVFGVIIPMPTEFHAFKLQLGD
-----MSSQKRRIIGAMCAIEREFGMIKKCFEK
-----------MIIGILAPMKEELQAICDKYPQ
--MASGTTTTAVKIGIIGGTGLDDPEILEGRTE

EC
GI MTN-1
GI MTN-2
EH
MTAP

---RQTISLGGCEIYTGQLNGTEVALL-KSGIG
KESYKEEVIAGRKYFTKLFEKYTLVLC-ECGIG
E--LQSEDHCGRTFYTGEISGQTVVIS-KSGIG
---STMLEKCGIHYHYIKIKDNEIIIM-QCGVG
KYVDTPFGKPSDALILGKIKNVDCVLLARHGRQ

EC
GI MTN-1
GI MTN-2
EH
MTAP

------KVAAALGATLLLEHCKPDVIINTGSAG
------KVCSGTAAVVLLDHFNADVIVAAGVAG
------KVAAASTAAIMISVFGCSEVIFLGVAG
------KVNAALAVSTIKHLFNVDIIINLGSAG
HTIMPSKVNY-QANIWALKEEGCTHVIVTTACG

EC
GI MTN-1
GI MTN-2
EH
MTAP

GLAPTLKVGDIVVSDEARYHDAD-VTAFGYE-GLKEGIAIGDVIVVDSVMQHDFN-CYPFVPRHT
GIQGRAAIGDVVVSTAAIQHDFD-GRPWVERSV
GMKLGQKPLDIVIGTELVYTDVD-ITPLGFA-SLREEIQPGDIVIIDQFIDRTTMRPQSFYDGSH

EC
GI MTN-1
GI MTN-2
EH
MTAP

---YGQ--LPGCP----------AGFKADDKLI
IVNIGVDVMHADKALTTTLQGIAEEFLKKNYST
VFSVGKCEIPADGQLQTRAQAAVQAVLADDMAL
---YGE--LLGEP----------KSWFSDKELV
SCARGVCHIPMAEPFCP-----------KTREV

EC
GI MTN-1
GI MTN-2
EH
MTAP

---------AAAEACIAELNLNAVRGLIVSGDA
IVP----P-CV-RETHGLSWPRLHVGCSISGDK
VLDDNSEPIGRRILAQLNRSPKLLTGSVLSGDQ
---------SLATKCSSSDLPTIHYGTIGTSDA
LIE-TAKKLG--LRCHSKGTM-----VTIEGDR

EC
GI MTN-1
GI MTN-2
EH
MTAP

FINGSVGLAKIRHNF-PQAIAVEMEATAIAHVC
FLENVDEKMELIKRI-PAALVIEMEGGAVGQVC
FVSSDEMNKELGSRF-ESALCVEMEGAAVAQIC
FVSAPMVQS-IQNKFDNRIVCAEMEGCAVAHSC
FSSRAESFM--FRTW--GADVINMTTVPEVVLA

EC
GI MTN-1
GI MTN-2
EH
MTAP

HNFNVPFVVVRAISDVAD-QQ--SHLSFDEFLA
YEASKPFVSLRIVSDLCD-GN--GLDNYDAYCT
YEARVPYIIIRAISDSGS-GE--ATVQFDEFCN
TKLGIRFIVIRSLSDVPS-EDGKSHEKMMDYLS
KEAGICYASIAMATDYDCWKEHEEAVSVDRVLK

EC
GI MTN-1
GI MTN-2
EH
MTAP

VA----AKQSSLMVESLVQKLAHG--------HV----ASK--VLYAILSSFFAQVA-------GI----SSP--LMLAVLKSYLASASKFDYCA-RA----SHNASILVSRIIEQLIVN--------TLKENANKAKSLLLTTIP----QIGSTEWSETL

EC
GI MTN-1
GI MTN-2
EH
MTAP

----------------------------------------------------------------MSALIMIQFSIRCRHLTQRSPME-----------------------------------------HNLKNMAQSFVLLPRH-----------------

Figure 9.
Clustal W Alignment of MTN Sequences.
Sequence comparison of microbial MTNs to human
methylthioadenosine phosphorylase (MTAP) is shown.
Homologous residues are shaded. Catalytic amino acids
are shaded in black. Amino acid homologies to EC MTA
nucleosidase are as follows: 86% to EH; 77% to GI
MTN-1; and 68% to GI MTN-2.
While MTNs have conserved active site residues, they also have differences in the
active site that set them apart from human MTAP, and that may be exploitable for drug
design. For example, the substrate 2’ hydroxy binding pocket electrostatics in MTAP is
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positively charged, while it is negatively charged in MTNs (Figure 10, part A). Likewise,
the 5’-alkylthio binding cavity of the MTNs is more extended and open than that found in
the MTAP active site (Figure 10, part B). Thus, a drug that bears a positive charge at the
2’ hydroxy position of the ribose and a larger 5’-alkylthio chain would likely discriminate
between the MTNs and human MTAP (Lee, Cornell, Riscoe, & Howell, 2003).

Figure 10.
MTN vs. MTAP Active Site Electrostatic Maps. A comparison
of the (A) ribose, and (B) 5′-alkylthio binding cavities in MTAP and MTN
complexed with 5’-methylthiotubercidin (MTT), which is an analogue of the
substrate MTA. (Adapted from Lee et al., 2004.)

MTN inhibitors have been created based on the transition states of the substrate
MTA as it is cleaved to MTR and adenine. A transition state is an unstable structure that
occurs between the chemical structure of the substrate and the products of a reaction.
Transition states exist for only about 10 -13 sec and thus there is no way to directly
observe the structure of a transition state. However, it is known that enzymes bind tighter
to the transition state than they do to the substrate. Thus, transition state analogues
(TSAs) should make better inhibitors than mimics of the substrate (Schramm, 1998). An
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extensive body of work to create and test these TSAs has been reported by Dr. Vern
Schramm’s lab (Albert Einstein College) (Schramm 1998; Schramm et al., 2008; Singh et
al., 2004; Singh et al., 2005; Singh, Lee, Núñez, Howell, & Schramm, 2005; Guitterez et
al., 2009). These inhibitors, based upon the MTA transition state, are designed to bind
with a higher affinity than that of the native substrates (Figure 11, part A). The
substitution of large groups at the 5’-alkylthio position improves specificity. The TSAs
show extraordinary tight binding affinities for E. coli MTN, yielding Ki values ranging
from picomolar to femtomolar concentrations. Of note, even greater binding affinity was
found when the drug was designed to mimic the late transition state by extending the
bonds between the nitrogen on the ribose and the purine ring. This yielded Ki values into
the femtomolar level (Figure 9, Part B) (Singh, Lee, et al., 2005).
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Figure 11.
MTA Transition and its Analogues. (A) Schematic of the
substrate MTA as it goes through the transition from products to reactants. (B)
Early and late transition state analogues of the substrate MTA and their relative
Ki values.

Unfortunately, these TSAs have not proved to be particularly effective as
antibiotics against E. coli, showing only modest IC50 values, which only went as low as
the micro molar range (Gutierrez et al., 2009). However, Gutierrez et al. (2009) did show
the ability of TSAs to block quorum sensing and reduce biofilm production that are
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important virulence factors. Transport of these drugs into the cell may be a limiting
factor in their poor performance on E. coli (Longshaw et al., 2010). Interestingly,
pathogens like Borrelia burgdorferi, which are purine auxotrophs, showed a much
greater sensitivity to MTN inhibitors (Cornell, Primus, Martinez, & Parveen, 2009). The
cause of this increased sensitivity could be due to the fact that these organisms are more
reliant on the salvage of methionine and purines that could make them more susceptible
to MTN inhibition (Cornell et al., 2009).
In-silico Computational Drug Discovery
Historically, drugs were discovered either serendipitously (like Penicillin) or by
looking closely at a folk remedy to find the active ingredient (like salicylic acid from
willow bark) (Houbraken, Frisvad, & Samson, 2011; Sneader, 2000). The drug
discoverers did not know how these drugs worked at first. They were limited by an
inability to see the mechanisms of pathogenesis at work in a disease process or the drug
reaction mechanisms. However, they could make better drugs by implementing small
chemical changes to known drugs and monitoring the results.
In 1958, the first X-ray crystallographic structure for myoglobin was reported
(Kendrew et al., 1958). Since that time, X-ray crystallography has been used to examine
thousands of structures of proteins in the presence or absence of bound substrate or other
ligands. This has allowed enzyme reaction mechanisms to be viewed for the first time,
and expanded the ability of scientists to rationally design drugs.
By the mid 1980s, computer renderings of bio-molecules from X-ray
crystallography, NMR, or homology modeling were beginning to be widely available.
These could be manipulated and the free energy measured for theoretically bound
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ligands. This further opened the window for the rational design of drugs (Anderson,
2003). This process has come to be called structure based drug design or in-silico based
drug design (Anderson, 2003; Jorgensen, 2004). Some success with this method was
reported as early as 1990 with the discovery of human immunodeficiency virus (HIV)
protease inhibitors (Roberts et al., 1990; Erickson et al., 1990). In the early years, the
method was limited by the difficulty of attaining drug-binding affinities through
computational measurement that were in good agreement with the experimental data
(Salemme, Spurlino, & Bone, 1970). By 2009, however, in-silico drug screening
approaches were responsible for finding anti-HIV fullerene derivatized amino acids that
had computational binding scores with HIV-1 protease that were within 10% of
experimental binding energies (Durdagi et al., 2009).
As computer modeling of biomolecules has improved, the composition of
computational drug lead libraries has also advanced. In 2006, small molecule databases
were used to custom build inhibitors to HIV-1 integrase (Jaganatharaja & Gowthaman,
2006). The use of chemical fragment libraries, which greatly increase the variety of
chemical possibilities and therefore greatly increases the hit rate for new drug leads, has
become a major contributor to the speed and ease of novel drug discovery (Hajduk &
Greer, 2007). By 2014, in-silico methods have become so reliable that they were used to
identify allosteric inhibitors of HIV-1 protease (Kunze et al., 2014).
In order to accomplish new drug discovery from x-ray crystallographic structures,
a reliable assay to monitor the bio-molecular process is needed. With the best estimation
of the binding site free energy, protein structure, and automated physical screenings
utilizing pre-synthesized drug libraries, high throughput screening (HTS) processes have
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been developed to identify new drugs. HTS allows large numbers (~ 105) of chemical
compounds to be examined for “lead discovery” (Terstappen & Reggiani, 2001).
The use of in-silico methods and HTS has a proven track record in development
of drugs against HIV (HIV protease inhibitors, etc.) and cancer (Gleevec) (Hajduk &
Greer, 2007). But use of this technology is not limited to these diseases. In fact, any
disease with a known macromolecular target would make a good candidate for this type
of drug discovery method, and this is precisely why this approach was used in our study.
Since there are homology models of Giardia and Entamoeba MTN’s (to E. coli MTN)
available for computational manipulation, it is logical to employ in-silico methods to find
new drug leads to inhibit their action. This is the approach our collaborator, Dr. Danny
Xu (Idaho State University, School of Pharmacy), took to identify a set of potential MTN
inhibitors. He used in-silico drug discovery methods to screen compounds in the NCI
Diversity Set II small molecule library against known E. coli MTN crystallographic
structures, and homology models of E. histolytica and G. intestinalis MTNs. Free energy
calculations of drugs were used to identify thirty-three compounds with favorable binding
into MTN active sites. Examples of three lead compounds bound to the active site of E.
coli MTN are shown in Figure 12. The structures show extensive interactions between
the compounds and the active site residues known to be involved in catalysis (e.g., Glu12,
Asp197, etc.).

25

Figure 12.
E. coli MTN Active Site Electrostatic Maps with
Bound Inhibitors. Box A and B show inhibitor 5A, C and D show
drug 15A and E and F show drug 27A bound.
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Summary
MTN is a necessary enzyme for Giardia and Entamoeba metabolism and is thus
an excellent target for novel anti-parasitic drugs. Inhibition of MTN causes
accumulations of SAH, MTA, and 5’dADO, which negatively impacts SAM metabolic
pathways. The inability to salvage methionine and purines, and the resulting impairment
to SAM pathways, likely causes parasite cell death due to nutrient depletions and
interruption of energy metabolism. While previously reported bactericidal activity of
MTN inhibitors is modest, their ability to modulate virulence in these pathogens shows
that it has potential as a broad spectrum treatment (Knippel, 2013).
In the following chapters, thirty-three potential MTN inhibitors found through insilico methods were analyzed for in vitro activity in enzymes and cell proliferation
assays. The inhibitors were tested using a spectrophotometric enzyme assay against E.
coli MTN, G. intestinalis MTN-1, G. intestinalis MTN-2, E. histolytica MTN, and human
MTAP. The inhibitors were also tested for in vitro anti-parasitic activity against G.
intestinalis trophozoites in resazurin reduction and BacTiter-Glo™ assays, and for antiproliferative activity against human Hela and Jurkat cell lines using the resazurin
reduction assay. These tests identified four drug lead compounds that showed low
micromolar to submicromolar affinities for parasite MTNs, and inhibited 50% of Giardia
growth at concentrations of 10-90 micromolar. Furthermore, several of the compounds
could effectively discriminate between the parasite MTNs and human MTAPs. The
results of this work show that four inhibitors were identified that are potential lead
compounds and support their further drug development.
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CHAPTER TWO: MATERIALS AND METHODS
Induction and Purification of Recombinant Enzymes
The genes encoding Giardia MTN-1, Giardia MTN-2, and Entamoeba MTN
were amplified and cloned into E. coli expression vectors in prior work (Bonander &
Cornell, 2007; Ormond, Simkin, & Cornell, 2007). Briefly, gene specific PCR primers
were used to amplify the target genes and clone them into pTrcHis-TOPO® plasmid
vectors (Invitrogen) to create chimeras encoding hexahistidine sequences fused to the Cterminus of the MTN enzymes. The plasmids were transformed and expressed in E. coli
BL21 (DE3) pLysS cells maintained on Luria Bertani (LB) agar supplemented with
100µg/mL ampicillin. The clone for E. coli MTN was maintained and expressed as
previously reported (Cornell & Riscoe, 1998; Lee, Cornell, Riscoe, & Howell, 2001). A
plasmid clone for hexahistidine tagged human MTAP (kind gift of Dr. V. Schramm,
Albert Einstein) was similarly transformed into E. coli BL21 (DE3) pLysS cells.
Recombinant enzymes were expressed as previously described (Cornell & Riscoe,
1998). Briefly, isolated bacterial colonies were used to inoculate a 10 mL culture of LB
broth supplemented with 100µg/mL ampicillin (LBamp100) and grown overnight at 37˚ C
with shaking. Induction cultures were initiated by diluting the overnight culture into 500
mL of fresh LBamp100 broth and incubating at 37˚ C with shaking (225 RPM) until the
optical density of the culture at 600 nm (OD600) reached 0.5. Recombinant protein
expression was induced by addition of isopropylthiogalactoside (IPTG) to 1.0 mM final
concentration. Cultures were induced overnight at 30˚ C. Cells were harvested via
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centrifugation at 4000 xg for 10 min. The bacterial cell pellet was washed in sterile PBS
and re-centrifuged at 4000 xg. Cells were lysed using either sonication or B-PER™
reagent (Pierce, Rockford, IL) and centrifuged at 12,000 xg for 15 min to remove debris.
Recombinant proteins were purified from the clarified lysate by cobalt affinity
chromatography using His-Pur Cobalt™ resin according to the manufacturer’s
specifications (Pierce, Rockford, IL). Briefly, the clarified lysate was mixed with an
equal volume of His-Pur Cobalt™ resin and rocked overnight at 4˚ C to bind the
recombinant enzymes. The resin was recovered by centrifugation at 700 xg for 2 min at
4˚ C to remove unbound material. The resin was sequentially washed with two 6 ml
volumes of 1 mM imidazole buffer (pH 7.2), and one 6 mL volume of 20 mM imidazole
buffer (pH 8) to remove weakly bound protein. Recombinant hexahistidine-tagged MTN
and MTAP enzymes were specifically eluted with three 3 mL volumes of 500 mM
imidazole (pH 8.0). Residual protein was stripped from the resin using one 3 mL elution
with 1 M imidazole (pH 8.0). Protein concentrations in fractions were estimated using a
Bio-Rad microassay (Bio-Rad, Hercule, CA) modification of the Bradford assay
(Bradford, 1976). Glycerol was added to enzyme containing fractions to a final
concentration of 20%, and the fractions stored -80 ˚C.
Analysis of MTN and MTAP Proteins
Affinity purified MTN and MTAP enzymes (5-10 µg) were analyzed for
homogeneity on 12% acrylamide SDS-PAGE gels electrophoresed at 66 mA for 45
minutes. Proteins were visualized by Coomassie Brilliant Blue staining (0.1%
Coomassie Brilliant Blue in 50% methanol/10% glacial acetic acid). Molecular weight
was confirmed by comparison to an EZ-Run Pre-stained Rec Protein standard (Thermo
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Fisher Scientific, Rockford, IL). Gel images were collected using a ProteinSimple
FluorChem E imager.
Determination of Protein Concentration
The concentration of purified proteins were determined by UV spectrophotometry
at 280 nm using a Varian Cary 50 spectrophotometer and the application of Beer’s law,
A=lc (Simonian, 2004). The extinction coefficients at 280 nm (280 were determined
using the Expasy ProtParam tool (www.expasy.org), and were as follows: EH MTN
0.592 mg/ml-1cm-1, GI MTN-10.618 mg/ml-1cm-1, GI MTN-2 0.404 mg/ml-1cm-1, and
human MTAP 0.959 mg/ml-1cm-1.
MTN Activity: Enzyme Assays
The specific activity of purified MTN and MTAP enzymes was determined by
monitoring the loss of absorbance at 275 nm (=1.6 mM-1 cm-1) that occurs when MTA
is cleaved into MTR and adenine (Singh, Evans, et al., 2005). Enzyme reactions
contained 0.1 M potassium phosphate buffer (pH 7) and 100 µM MTA with a total
volume of 990 µl. The assay was initiated by addition of enzyme (1-4 µg) in 10 µL and
rapid mixing. A Varian Cary 50 spectrophotometer was used to measure absorbance
changes at 275 nm and the specific activities calculated in U/mg (1 U = 1 µmol/min
MTA conversion). Enzyme kinetics assays were similarly performed using varying
substrate (MTA, SAH, 5’dADO) concentrations (1 – 100 µM). Results were plotted on
[S] vs. V graphs, and kinetic constants (Km, kcat) determined by fitting the data to the
Michaelis-Menten equation (Eq. 1) using GraphPad Prism (GraphPad Software, Inc., La
Jolla, CA).
(Equation 1)

Vo = Vmax [S]
Km + [S]
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MTN Inhibition Assay
Initial in-silico computational screening by Dr. Danny Xu (Idaho State University,
Meridian, ID) identified 33 potential competitive inhibitors of MTN based on screening
of the National Cancer Institute (NCI) diversity set II compound database (~4200
compounds) against known crystal structures for the E. coli MTN. The 33 potential
inhibitors were obtained from the NCI and analyzed for in vitro anti-MTN activity using
the UV spectrophotometric assay (275 nm) described above. In the assay, MTA substrate
concentrations (20 – 200 µM) and inhibitor concentrations (0 – 100 µM) were used.
Inhibitor constants were determined by two methods. In the first method, velocity
measurements were collected at a constant substrate concentration with varying inhibitor
concentrations (Singh, Evans, et al., 2005). The ratio of inhibited to uninhibited velocity
(Vo’/Vo) was plotted as a function of inhibitor concentration. Inhibitor constants (Ki’s)
were obtained by fitting the results to the equation for competitive inhibition (Eqn. 2).
(Equation 2)

Vo’/Vo = (Km + [S]) / {(Km + [S]) + (Km[I]/Ki)}

In the second method, several inhibitor concentrations were tested for effects against
increasing substrate concentrations. The resulting substrate-velocity data was fit to
equations for competitive (Eq. 3), uncompetitive (Eq. 4), and mixed inhibition (Eq. 5)
using GraphPad Prism. The “best fit” was assigned based on r2 values.
(Equation 3)

Vo = (Vmax [S]) / {Km (1 + [I]/Ki) + [S]}

(Equation 4)

Vo = (Vmax [S]) / {Km + [S](1 + [I]/Ki)}

(Equation 5)

Vo = (Vmax [S]) / {Km (1 + [I]/Ki) + [S](1 + [I]/Ki)}
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Cell Growth Assays
Giardia intestinalis Resazurin Reduction Assay
Giardia intestinalis (clone WB C6) cells were grown at 37 ˚C in sealed T-25
flasks containing in sterile TYDK media (Valdez et al., 2009) supplemented with adult
bovine serum (Thermo Scientific), Ox bile (MP Biomedicals, Solon, OH), Fungizone
(Omega Scientific Inc., Tarzana, CA), and Pen-Strep (Thermo Scientific). To prepare
cultures for antibiotic tests, cells were harvested from near-confluent culture by placing
on ice up to one hour promote cell detachment. The detached-cell sample was split
between two 50 ml conical tubes and centrifuged at 500 xg for 5 minutes to pellet the
cells. The supernatant was then decanted and cells were re-suspended into 5 mL of fresh
TYDK broth. The cell concentration and viability was determined using a
hemacytometer and Trypan blue staining (Sigma), and the cell suspension volume
adjusted with TYDK broth to obtain a concentration of 1 x 106 trophozoites/ml.
Antibiotic activity studies were conducted in 96 well plates containing drug (0 –
100 µM), TYDK broth, and 1 x 104 Giardia trophozoites in a final volume of 300 µL.
The standard anti-giardial agent metronidazole (MTZ) served as a control in drug
sensitivity studies. Plates were sealed with thin film and incubated in anaerobic chambers
at 37 ˚C for 64 hours. The media in the wells was then replaced with 300 µl of 0.1%
resazurin (MP Biomedicals) in PBS supplemented with 0.1% glucose. Fluorescence
measurements were made using on a BioTek Synergy HT plate reader (Em. 530 nm/Ex.
590 nm), and the plates returned to the anaerobic chamber. Additional fluorescence
readings were conducted at 68 and 72 hr.
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Giardia intestinalis BacTiter-Glo™ Assay
Additional drug sensitivity studies were conducted as previously described
(Debnath et al., 2012; Tejman-Yarden et al., 2013). In brief, sterile opaque-walled 96
well plates were assembled containing Giardia intestinalis cells (104 trophozoites/well)
and drug (0-100 µM) in a final volume of 100 µL TYDK media. Metronidazole
treatment (0-100 µM) served as a control. Plates were placed in an anaerobic chamber
and incubated at 37˚ C for 72 hrs. Cell proliferation was measured by assessing ATP
content by the addition of 100 µL BacTiter-Glo™ reagent (Promega, Madison, WI) to
each well. Luminescence was recorded for five minutes using a BioTec Synergy HT
plate reader.
Mammalian Cell Line Resazurin Reduction Assays
Hela cells were cultured at 37˚ C in a 5% CO2 humidified atmosphere using
Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% FBS and PenStrep. Cells were harvested by brief treatment with Trypsin-EDTA (MP Biomedicals),
dilution of detached cells with 10 mL DMEM, and centrifugation at 250 xg for 5 minutes.
The cell pellet was resuspended in 10 mL fresh DMEM and the viability and density
determined by Trypan blue staining and hemacytometry. Cells were diluted to a final
concentration of 25,000 cells/mL, and 200 µl of cells and media were pipetted into each
well of a sterile 96 well plate. Plates were incubated at 37 ˚C for 24 hr in a 5% CO2
humidified atmosphere. After 24 hr, media was replaced with 200 µl of fresh media
containing 0-100 µM drug. Plates were cultured for an added 48 hr, at which time 20 µl
of 0.1% resazurin in 1X PBS was added to each well, and the plates re-incubated for
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another 24 hrs. At 72 hr, fluorescence (Ex. 485 nm/Em. 528 nm) was measured using a
BioTek Synergy HT plate reader.
Jurkat cells were cultured at 37˚ C in a 5% CO2 humidified atmosphere using
RPMI 1640 media supplemented with 10% FBS and Pen-Strep. Cells were harvested by
centrifugation and the cell pellet resuspended in media to a final concentration of 5.5 x
104 cells/mL. Drug sensitivity plates contained 0-100 µM drug and 1 x 104 Jurkat
cells/well in a final volume of 200 µL. At 48 hr, 20 µl of 0.1% resazurin in 1X PBS was
added to each well. At 72 hr, fluorescence measurements (Ex. 485 nm/Em. 528 nm)
were made using a BioTek Synergy HT plate reader.

34

CHAPTER THREE: RESULTS AND DISCUSSION
Purity and Activity of Proteins
Milligram quantities of overexpressed recombinant enzymes were purified by
cobalt affinity chromatography. Protein purity was confirmed by SDS PAGE (Figure
13). All the enzymes showed > 95% purity. The molecular weights for Entamoeba
MTN (EH, 29,434 D), Giardia MTN-1 (33,034 D), and MTN-2 (35,773 D) calculated
from the molecular weights of enzyme monomers fused to the affinity sequences derived
from the pTrcHis-TOPO® vector using the Expasy Protparam tool (www.expasy.org)

STD EH MTN-1 MTN-2

Figure 13.
SDS-PAGE of Recombinant
Proteins. Cobalt affinity purified enzymes were
electrophoresed on a 12% polyacrylamide gel.
All three enzymes showed greater than 95%
purity. Estimated molecular weights for the
enzymes were 29 kD (EH), 33 kD (GI MTN-1)
and 36 kD (GI MTN-2).
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were consistent with the apparent molecular weights estimated from the gel.
Previous specific activity measurements performed at saturating concentrations of
MTA, 5’dADO, and SAH substrates demonstrated that both MTA and 5’dADO were
substrates for all three parasite enzymes (Bonander & Cornell, 2007; Ormond, et al.,
2007; Stone, Eidemiller, & Cornell, 2012). SAH was not a substrate for EH MTN and GI
MTN-1, but was a substrate for GI MTN-2 (Stone et al., 2012). EH, GI MTN-1, and GI
MTN-2 showed specific activities for MTA of 11.0, 0.3, and 0.2 U/mg (1 U =
1µmol/min), respectively, and 5.0, 0.3, and 0.2 U/mg for 5’dADO. These specific
activities are lower than those reported for the bacterial E. coli MTN (4.4 U/mg) or B.
burgdorferi MTN (4.1 U/mg) (Cornell, Swarts, Barry, & Riscoe, 1996; Cornell, et al.,
2009). However, it is in good agreement with data collected previously on EH and GI
MTN-1 proteins purified previously in the Cornell lab that showed specific activities for
MTA of 11.5 and 0.37 U/mg, respectively, and 5.9 and 0.24 U/mg, respectively, against
5’-dADO (Hall, Martinez, & Cornell, 2012). It appears that the eukaryotic MTNs display
less activity overall. Consistent with this observation, the MTN of the tomato fruit
(Lycopersicon esculentum) appear to show a maximum activity of only 0.0012 U/mg
protein, though this protein was purified from native sources and was not a pure
recombinant source (Kushad, Richardson & Ferro, 1985).
To prepare for later inhibition studies, the kinetic constants for MTA and 5’dADO
were determined for the three parasite enzymes. A representative substrate-velocity graph
for the activity of GI MTN-1 is presented in Figure 14. Additional substrate-velocity
graphs are presented in Appendix B. The results of kinetic analyses for the three parasite
enzymes and E. coli MTN are summarized in Table 2. In general, the parasite enzymes
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demonstrated Km values for MTA in the 2 – 5 µM range, approximately an order of
magnitude larger than the Km for MTA found for the E. coli enzyme (0.5 µM). In
Arabidopsis MTNs, Km values reported for MTA were both above 20 µM, while in
Lupines luteus seeds the Km value reported for MTA was only 0.41 µM (Park et al.,
2009; Guranowski, Ghiang, & Cantoni, 1981). However, other authors have reported Km
values for MTA of 2.1 µM in Oryza (rice) and 3.4 -7.1 µM in Arabidopsis, which are
similar to the Km values reported here for the parasite enzymes (Rzewuski et al., 2007;
Siu et al., 2008). A Km value of 8.7 µM for MTA was also reported for the MTA/SAH
nucleosidase of Klebsiella pneumonia that shares closer homology to the proteins studied
here (Cornell, Winter, Tower, & Riscoe, 1996). Overall, it is important to note that, just
as was reported to be the case in Burkholderia thailandensis, these enzymes all share one
common trait, they have a greater specificity for MTA than for the other possible
substrates (Gao, Zheng, & Yuan, 2013).
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Figure 14.
Substrate-velocity Graph of GI MTN-1 for MTA. Kinetic
constants were determined by fitting the data to the Michaelis-Menten equation
using GraphPad Prism. Km and kcat values represent the means ± SD for three
replicates. Substrate-velocity plots for additional enzymes and substrates are
found in Appendix B.

As seen in Table 2, the E. coli MTN also showed greater catalytic efficiency for
the substrates than the parasite enzymes. Generally, the catalytic efficiencies (kcat/Km)
were best for the MTA substrate, indicating that it is the preferred substrate of the
parasite enzymes.
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Table 2

Summary of Recombinant Parasite MTN Substrate Kinetics
-1

-1

-1

Substrate
MTA
5'dAdo
SAH

Km (µM)

kcat (s )

kcat/Km (s µM )

0.5 ± 0.2
0.8 ± 0.2
1.3 ± 0.2

1.7 ± 0.1
3.0 ± 0.1
2.6 ± 0.1

3.4 ± 0.5
3.6 ± 0.7
2.1 ± 0.3

EH MTN

MTA
5'dAdo
SAH

4.5 ± 0.4
3.8 ± 0.7
NA

5.3 ± 0.1
2.4 ± 0.1
NA

1.2 ± 0.3
0.6 ± 0.1
NA

GI MTN-1

MTA
5'dAdo
SAH

2.3 ± 0.3
9.8 ± 1.5
NA

0.2 ± 0.01
0.2 ± 0.01
NA

0.09 ± 0.03
0.02 ± 0.001
NA

GI MTN-2

MTA
5'dAdo

5.3 ± 1.0
10.7 ± 1.7

0.1 ± 0.01
0.1 ± 0.01

0.02 ± 0.006
0.01 ± 0.006

Enzyme
E. coli MTN

A kcat/Km ratio of EH MTN was calculated as 1.2 s-1µM-1 for MTA and 0.6 s1

µM-1 for 5’dAdo, only half the value for MTA. The efficiency of GI MTN-1 was 0.09 s-

1

µM-1 for MTA and 0.02 s-1µM-1 for 5’dAdo, less than a third the value of MTA. The

efficiency of GI MTN-2 was 0.02 s-1µM-1 for MTA and 0.01 s-1µM-1 for 5’dAdo. These
numbers suggest a much higher efficiency of EH MTN compared to either of the Giardia
MTNs although the efficiency for MTA as a substrate is always the highest for all three
enzymes. The comparatively more active E. coli MTN, with a 3.4 s-1µM-1 efficiency for
MTA, can possibly be explained by a lack of an SAHH in its genome and also a lack of
other MTN proteins capable of catabolizing all of the substrates that build up inside the
cell. E. histolytica has an SAHH in its genome that would reduce the necessity for a very
active MTN enzyme. Interestingly, the plant Arabidopsis thaliana genome encodes two
MTNs and a SAHH, and the MTNs show efficiencies of 0.6-2.6 s-1µM-1 for MTA (Siu et
al., 2008). This is similar to the values reported here for the Entamoeba enzyme. Similar
to Arabidopsis, G. intestinalis encodes two MTNs. However, Giardia lacks an SAHH,
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and the efficiencies for MTA and 5’dAdo are lower than the other reported enzymes.
This suggests that the organism may use its MTNs to hydrolyze a variety of nucleosides
to supply purines for the cell, and thus the MTNs have low efficiency for any one
substrate. Or, the enzyme conditions for optimal activity have yet to be achieved. To date,
ten complete Giardia genome sequences have been submitted to the Uniprot database,
and all have contained two putative MTN genes. This may further support the idea that
the activity of each enzyme is of less importance than the combined activity of both of
the MTN enzymes.
MTN Inhibition Assays
The initial 33 compound hits from the in-silico screening (against E. coli MTN)
were tested by UV spectrophotometric assay for inhibitory activity against the E. coli
MTN. This resulted in the identification of four compounds with measurable inhibitory
activity (listed in Table 3). These four compounds were expected to be good inhibitors
against both the Giardia and Entamoeba MTNs because of the overall high homologies
in MTN active sites. Initial tests using equal concentrations of MTA substrate and drug
showed definite inhibition of parasite MTN activity.
Table 3

IUPAC Names of MTN Inhibitors

Drug

IUPAC Name

5A
8A
15A
27A

N-(2-furylmethyl)-N’-(4-nitrophenyl)urea
1-(4-nitrophenyl)-3-[4-[4[(4-nitrophenyl) carbamoylamimino] phenoxy]phenyl]-urea
2-[2-(5,6-dimethyl-1H-benzoimidazol-2-yl)vinyl]-5,6-dimethyl-1H-benzoimidazole
3-(1,3-benzothiazol-2-yl)-1-(5-{[(1,3-benzothiazol-2-yl)carbamoyl]amino}-2methylphenyl)urea

Inhibitor constants were determined for the four compounds using the method of
Singh, Evans, et al. (2005) that measures the ratio of the inhibited initial velocity to the
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uninhibited velocity as a function of the inhibitor concentration (Figure 15, left panel).
The results were fit to the Michaelis-Menten equation for competitive inhibition (Eqn. 2).
This method works well with high affinity competitive inhibitors, but is not readily useful
for inhibitors that bind by mixed or uncompetitive modes. Since the drugs were initially
identified by in-silico calculations of their capacity to bind the active site of the enzymes,
it is reasonable to assume that the primary mode of inhibition would be competitive, and
this generally is what was seen (Figure 16).

Figure 15.
Giardia MTN-1 Inhibition Kinetics for Drug 27A. Left panel: the
ratio of inhibited/uninhibited velocity (Vo’/Vo) was plotted as a function of
inhibitor concentration and fit to the equation for competitive inhibition using
GraphPad Prism. The competitive inhibition constant was 1.7µM. Right panel
is an example a substrate-velocity plot that measured the effect of 27A
concentration (0-10µM). In this graph, the best fit of the data was found using
the equation for mixed inhibition. The alpha value of 7.6 suggests that the
inhibition was predominantly competitive since it lies closer to 10 than to 1.

To determine if other modes of inhibition were occurring, and to attempt to find
Ki values for data that failed to readily fit the approach used by Singh, Evans, et al.,
inhibition constants were also determined by measuring the effect of varied
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concentrations of inhibitor (1-20 µM) across a range of substrate concentrations (1-50
µM). The results were presented as substrate (S) vs velocity (V) plots, and the data fit to
the Michaelis-Menten equation for competitive, uncompetitive, and mixed inhibition
(Eqs. 3-5) using GraphPad Prism. As can be seen in Figure 15 (right panel), the best fit
for drug 27A inhibition was obtained using the model for a mixed inhibitor. The alpha
value (7.6) indicates that competitive inhibition was the predominant contributor to the
mixed inhibition profile produced by drug 27A.
The software reported an alpha value that helped to determine the mode of
inhibition of each drug against each enzyme. If the alpha value, which can be seen in
Equation 6, was less than 1 then the mode was uncompetitive, when it is 1 then it is
noncompetitive, when it is greater than one but less than 10 then there is a mix of
uncompetitive and competitive, and if it is larger than 10 then the mode matches the
competitive model (GraphPad Prism User’s Manual).
(Equation 6)

ܸൌ

ሺ௫ሻሾௌሿ
ሾሿ

ሾሿ

൭ቆଵାቀ಼ቁቇ൱ା൭ሾௌሿቆଵାቀഀ಼ቁቇ൱

Compounds that inhibited the reaction the strongest showed the lowest Ki values.
When tested against E. coli MTN, compounds 5A, 8A, 15A, and 27A yielded Ki values
of 0.6, 0.05, 0.03, and 0.02 µM, respectively. All were competitive inhibitors of the E.
coli enzyme (Figure 16). These values are three to six orders of magnitude higher than
the Ki values of the nucleoside transition state analogs of MTA reported for E.coli MTN
(Singh et al., 2004; Singh, Evans, et al., 2005; Gutierrez et al., 2007). However,
transition state analogues have nearly perfect structure and electrostatics, which allow for
extremely tight binding (Lee et al., 2005). However, the purpose of looking at
compounds identified by in-silico screening (rather than transition state analogs), is that
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they are novel drug leads that do not resemble the substrates. Thus, they may show more
effective transport properties and more discrimination for pathogen MTNs. These
compounds will serve as lead scaffolds for further optimization studies.

5A
Ki (µM) α
EC MTN
0.6 ± 0.03
EH MTN
GI MTN-1
8.0 ± 3.1* 6.9 (M)
GI MTN-2
0.3 ± 0.1
Human MTAP 21.5 ± 3.5

15A
EC MTN
EH MTN
GI MTN-1
GI MTN-2
Human MTAP

Ki (µM)
α
0.03 ± 0.004
3.9 ± 1.4*
8.7(M)
40.6 ± 6.9*
1 (N)
7.2 ± 2.1
0.8 ± 0.3

8A
Ki (µM)
EC MTN
0.05 ± 0.01
EH MTN
0.5 ± 0.1
GI MTN-1
0.8 ± 0.2
GI MTN-2
6.3 ± 1.9
Human MTAP
4.3 ± 0.7

27A
Ki (µM)
α
EC MTN
0.02 ± 0.003
EH MTN
6.2 ± 2.8* 8.7 (M)
GI MTN-1
1.7 ± 0.3
GI MTN-2
Human MTAP 3.6 ± 0.6

Figure 16.
Summary of Ki values. Ki values were determined from Vo’/Vo vs.
[I] plots, or from Vo vs. [S] plots fit uncompetitive, competitive and mixed
inhibition profiles. Values for Ki with the * symbol were found using velocity (V)
vs substrate [S] and the equation for mixed inhibition and thus have an alpha
value which is a multiplicative factor associated with the Ki which tells the type
of inhibition which is occurring. M stands for mixed type, N is non-competitive,
U is uncompetitive and C is competitive type inhibition.
When tested against the parasite MTNs, the inhibitors mostly displayed high
nanomolar to low micromolar inhibition constants. Compound 5A failed to inhibit the
Entamoeba MTN, but showed a 0.3 µM competitive inhibition constant for Giardia
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MTN-2 and mixed inhibition against MTN-1. Overall, compound 8A showed some of
the most potent inhibition profiles for the parasite enzymes. Compound 8A showed strict
competitive inhibition with 0.5-0.8 µM inhibition constants against Entamoeba and
Giardia enzymes. While compounds 15A and 27A showed the tightest binding to E. coli
MTN, their binding profiles were the weakest to the parasite MTNs.
An indication of drug specificity for target MTNs was gained by examining
inhibition profiles against human MTAP, as has been previously reported for transition
state analogs of MTA (Longshaw et al., 2010). This difference suggests that use of these
drugs against a target organism will not cause serious side effects in the host. It is also
unlikely that drug inhibition of MTAP by a drug used only in the short term would cause
any permanent harm to the human host. In addition, transition state analogs that were
found to be more potent against MTAP rather than target MTNs may make attractive
anti-cancer agents, although that is beyond the scope of this thesis (Clinch et al., 2012;
Singh et al., 2004). The initial in vitro testing showed that most of the compound Ki
values were higher for human MTAP than seen for the microbial MTNs. The exceptions
were 15A and 27A, which showed tighter binding to the human MTAP than most of the
parasite MTNs.
Table 4 summarizes the Ki discrimination factors found for the four inhibitors.
These discrimination factors were obtained by dividing the MTAP drug Ki by the MTN
drug Ki values (Longshaw et al., 2010). Larger discrimination factors are desirable, since
they indicate more specificity for the target MTNs. All four compounds showed high Ki
discrimination factors (35.8 to 157.0-fold) for the E. coli MTN compared to human
MTAP. However, for the parasite MTNs, only compound 5A showed a high
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discrimination factor (65.1-fold) for GI MTN-2 compared to MTAP. The other
discrimination factors were either modest, or showed a preference for human MTAP. The
development of larger discrimination factors will be a primary goal of drug optimization.
Table 4

Summary of Drug Discrimination Factors

Drug

Ki MTAP/
Ki E.coli MTN

Ki MTAP/
Ki EH MTN

Ki MTAP/
Ki GI MTN-1

Ki MTAP/
Ki GIMTN-2

5A

35.8

NA

6.1*

65.1

8A

79.3

8.4

5.3

0.7

15A

25.3

0.2*

0.2*

0.1

27A

157.0

0.9*

2.1

NA

NA means a Ki value could not be determined. * indicates discrimination factors
determined using mixed inhibition Ki values for the MTN.

Giardia intestinalis Drug Sensitivity
The ability of MTN inhibitors to exert antiproliferative effects against Giardia
intestinalis trophozoites (WB clone G6) was examined using a resazurin reduction assay
(Nillius, Müller, & Müller, 2011; Bénéré, de Luz, Vermeersch, Cos, & Maes, 2007) that
follows the conversion of resazurin to fluorescent resorufin in viable cells (Figure 17). In
this assay, the fluorescence signal strength can be correlated to viable cell number and
used to estimate drug IC50 values. Unfortunately, this test is susceptible to media
interferences. TYDK media used to grow Giardia causes nonspecific reduction of
resazurin, resulting in elevated background signals that limit assay sensitivity. To bypass
this effect, the media in the assay is replaced with PBS-glucose containing the resazurin
dye. However, this adds to the labor involved in the assay and potentially introduces error
to the experiment.
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Figure 17.
Resazurin reduction assay. Living cells reduce the blue resazurin
dye to the strongly fluorescent magenta resorufin (Ex. 485 nm/Em. 528 nm).

Resazurin reduction assays were subsequently repeated using the BacTiter-Glo™
assay that has been reported to show fewer media interferences and greater sensitivity
and accuracy (Valdez et al., 2009). This assay directly measures ATP concentration,
which is high in metabolically active cells and rapidly lost in dead cells (Figure 18).

Figure 18.
BacTiter-Glo™ reaction. Luciferase decarboxylates luciferin in
an ATP, molecular oxygen, magnesium cation dependent reaction to generate
a photon of light that can be measured by luminescence.

Drugs 5A and 8A seemed to be the most efficient at killing the Giardia
trophozoites in the resazurin reduction assay (Figure 19, left panel), with approximate
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IC50 values of 24.5 and 22.2 µM, respectively (Table 5). Since both of these compounds
also exerted submicromolar Ki values for at least one of the Giardia MTNs, these two
seem to be the most desirable of the four compounds to further develop. The compounds
15A and 27A also killed Giardia, but with IC50 values of 80-90 µM. These compounds
could still be viable candidates for use as anti-parasitics after more optimization. The
results seem to roughly correlate with the in vitro Ki values, which suggested that 5A and
8A are better inhibitors of Giardia MTN than are drugs 15A and 27A.

100

% Cell Viability

% Cell Viability

100

50

5A
8A
15A
27A
Metronidazole

50

0

0
1
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[drug] M

1

10

100

[drug] M

Figure 19.
Giardia intestinalis Drug Sensitivity Graphs. Left panel- Giardia
sensitivity to MTN inhibitors using the resazurin reduction assay. Right panelGiardia to MTN inhibitors using the BacTiter-Glo assay. Metronidazole
sensitivity was measured in each assay as a drug treatment control.

The IC50 concentrations found using the BacTiter-Glo™ method (Figure 19, left
panel; Table 5) were consistently lower than those found using the resazurin reduction
assay. Drug 5A (IC50 = 10.8 µM) actually outperformed any of the other drugs in this
assay, with the exception of the metronidazole (IC50 = 1.9 µM). Drugs 8A and 27A were
slightly less potent, with IC50s of 12.3 and 16.12µM, respectively. The weakest inhibitor
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was 15A with an IC50 of 78.9 µM. These results suggest that the enzyme Ki values were
fairly good predictors of anti-giardial activity: tighter binding drugs (lower Ki’s) showed
more potent activity in vitro against parasite cultures.
None of the compounds were as potent as metronidazole (IC50 = 1.4-1.9 µM), or
the recently reported Auranofin (IC50 = 4-6 µM) (Tejman-Yarden et al., 2013). However,
the MTN inhibitors are intended as lead compounds that will be further optimized via
derivatization of the compound to lower their IC50 values and improved their
discrimination for parasite MTNs. In this regard, the testing of putative MTN inhibitors
identified by in-silico screening has been a success. Several compounds, 5A in
particular, showed the ability to discriminate between the parasite and human enzymes,
and showed in vitro activity against parasite cultures.
Human Cell Line Drug Sensitivity
The drug leads were reasonably non-toxic to HeLa cell cultures, with the
exception of drug 8A, which showed an IC50 value of 6.2 µM (Figure 20, left panel;
Table 5). The other drugs (5A, 15A, 27A) showed IC50 values in excess of 400 µM,
dramatically higher than their corresponding IC50s for parasite cultures (Table 5). These
results suggest that 8A would not make a great anti-parasitic without optimization, but
instead may make an attractive anti-cancer agent. It is interesting to note that drug 8A
actually had one of the higher Ki values against human MTAP in the in vitro enzyme
activity tests. This may indicate that there is some other mechanism of action that is
causing the drug to be lethal to the HeLa cells other than strict inhibition of MTAP.
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Figure 20.
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Human Cell Line Sensitivity to MTN Inhibitors. Left panel: HeLa
cell line sensitivity. Right panel: Jurkat cell line sensitivity.

The results from that analysis of anti-proliferative effects on Jurkat cells pose
more of a problem for the drugs as possible anti-parasitic candidates. While the general
pattern found in the HeLa cells seems to be repeated, the one notable exception is that
drug 27A appears to kill Jurkat cells almost as well as drug 8A. The 8A IC50 for Jurkat
cells is 3.3 µM, well below the 12-22 µM IC50 for Giardia. Drug 27A follows close
behind with an IC50 of 7.1 µM. Again, drug 5A appears to be most promising, with an
IC50 of 131.9 µM against Jurkat cells, well above the IC50 shown for Giardia. 15A seem
to have about the same IC50 level for Jurkat cells as they did for Giardia, 71.4 µM and
90.1 µM, respectively. It is important to note that Jurkat cells are a highly proliferative
cell line, which may mean that they are more reliant on MTAP for purine and methionine
salvage than other cells, and are thus more sensitive to the MTN inhibitors studied here.
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Table 5

Summary of Drug IC50 Values (in µM)
5A

Inhibitor IC50 (µM ± SEM)
8A
15A
27A

MTZ

Giardia

24.5 ± 1.71
10.8 ± 1.42

22.2 ± 1.51
12.3 ± 1.22

90.1 ± 1.41
78.9 ± 1.22

79.7 ± 1.51
16.2 ± 1.22

1.4 ± 1.61
1.9 ± 1.32

Hela
Jurkat

421.1 ± 1.1
131.9 ± 1.3

6.2 ± 0.9
3.3 ± 1.3

868.2 ± 1.0
71.4 ± 1.3

438.7 ± 1.3
7.1 ± 1.4

NA
NA

1

Results from resazurin reduction assay (Nillius et al., 2011; Bénéré et al., 2007).
Results BacTiter-Glo™ assay (Valdez et al., 2009). NA means not applicable. Values
represent the average of at least three experiments ± SEM.
2
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CHAPTER FOUR: CONCLUSION
The emergence of drug resistance in parasitic protozoa, and the likelihood of
continued expansion of that resistance to other parasites, is a cause of major concern to
health authorities. This alarming situation creates a need to develop novel anti-parasitic
agents. Promising drug leads have been found through in-silico computational drug
screening methods. These drug leads appear to target the parasitic forms of the MTN
enzyme with high binding affinities while binding the human correlate enzyme MTAP
with a lesser affinity as was predicted by the computer simulations. A positive association
was found between MTN inhibition and drug IC50 values against the target organism,
Giardia intestinalis. This suggests that the drug activity is due to the inhibition of the
parasitic MTN and not due to other possible off-target effects of the drugs. This study
has proved that in-silico methods can be employed to discover novel drug leads that are
effective against parasitic protozoan MTNs and serves to promote further in-silico studies
against other organisms that require MTN activity to salvage methionine and purines
from nucleoside by-products of SAM mediated reactions in the cell.
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Table A.1

Structures and Properties of the Best MTN Inhibitors

Short
Name

MW
(g/mol)

ε (µM-1 cm-1)
@λ (nm)

5A

261.233

0.028
@ 333.4

8A

528.473

0.050
@ 356.7

15A

316.4

0.038
@ 371.0

474.558

0.034
@ 306.0

27A

Structure
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I.

Entamoeba MTN Substrate Kinetics Graphs

Figure B1.
EH MTN Substrate Kinetic Graphs- Left graph is the enzyme velocity
with MTA as the substrate and at right is the velocity with 5’dAdo as the substrate.

II. Giardia MTN-1 Substrate Kinetics Graphs

Figure B2.
GI MTN-1 Substrate Kinetic graphs – Left graph is the enzyme
velocity with MTA as the substrate and at right is the velocity with 5’dAdo as the
substrate.
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III. Giardia MTN-2 Substrate Kinetics Graphs

Figure B3.
GI MTN-2 Substrate Kinetic Graphs- Top left graph is the enzyme
velocity with MTA as the substrate, at top right is the velocity with 5’dAdo as the
substrate and at the bottom is the velocity with SAH as the substrate.
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I.

Entamoeba MTN Inhibition Kinetics graphs

Figure C1. EH MTN Inhibition Kinetics Graphs- Each graph is the substrate v.
velocity of EH MTN against inhibitor 5A (top left), 8A (top right), 15A (bottom left),
and 27A (bottom right.)
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II.

Giardia MTN-1 Inhibition Kinetics Graphs

Figure C2. GI MTN-1 Inhibition Kinetics Graphs- Each graph is the substrate v.
velocity of GI MTN-1 against inhibitor 5A (top left), 8A (top right), 15A (bottom
left), and 27A (bottom right.)
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III.

Giardia MTN-2 Inhibition Kinetics Graphs

Figure C3. GI MTN-2 Inhibition Kinetics Graphs- Each graph shows the enzyme
GI MTN-2 being inhibited by drug 5A (left) and 8A (right). These graphs were
derived using the method of Singh, Evans et al., 2005.
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IV.

Human MTA Phosphorylase Inhibition Kinetics Graphs

Figure C4. Human MTAP Inhibition Kinetics Graphs- Each graph is the
substrate v. velocity of human MTAP against inhibitor 5A (top left), 8A (top right),
15A (bottom left), and 27A (bottom right.)
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APPENDIX D
Compounds Identified from In Silico Screening
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Table D.1

#
1

Compounds Identified from In-Silico Screening

Ligand ID
NSC ID
CAS #
MW
General class
ZINC01163259
4292
5397-96-6

thiazole

2

ZINC00035241
35241
6276-41-1
330.39

Name
1-(2-naphthyl)-2-[(6nitro-1,3-benzothiazol2-yl)thio]ethanone

1-(6-nitrobenzothiazol2-ylthio)-2phenylethan-1-one

thiazole

3

ZINC01668706
36317
No CAS
384.429
piperzine

N,N'-bis(4methoxyphenyl)piperaz
ine-1,4-dicarboxamide

4

ZINC01676023
43308
NO CAS
288.3
styrylidine

2-keto-4-phenyliminoN-styrylidene-but-3enamide

5

ZINC04776634
45086
NO CAS
261.233
Alkylurea/furan

N-(2-furylmethyl)-N'-(4nitrophenyl)urea

6

ZINC18154478
45545
NO CAS
307.284
Pyridine/quioline
ZINC13154298
55691
7713-86-2
493.238
thiazole

4-[(N'E)-N'-(2,4-dioxo1H-quinolin-3ylidene)hydrazino]benz
amide

7

Thiazole, 2,2'iminobis[4-(4bromophenyl)-

Structure
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1-(4-nitrophenyl)-3-[4[4-[(4nitrophenyl)carbamoyla
mino]phenoxy]phenyl]urea
1,4-bis(3,4-dihydro-1Hisoquinolin-2-yl)but-2ene-1,4-dione

8

ZINC04896601
80735
NO CAS
528.473
alkylurea

9

ZINC04900874
87838
NO CAS
346.422
Pyridine/quinoline

10

ZINC01569416
88600
NO CAS
376.9
piperzine

[4-(2chlorophenyl)piperazin
o]-(3,4dimethoxyphenyl)meth
anethione

11

ZINC23118772
91395
NO CAS
396.91
piperzine

1-[4-(3chlorophenyl)piperazin
yl]-3naphthyloxypropan-2-ol

12

ZINC29589828
91396
NO CAS
396.91
piperzine

13

ZINC29589833
91397(111210)
NO CAS
396.91
piperzine

14

ZINC29589837
91402
NO CAS
376.491
piperzine
ZINC04878491
92833
NO CAS
316.4
imidazole
ZINC00111210
111210
NO CAS
348.421
indazole

(2R)-1-[4-(2chlorophenyl)piperazin1-yl]-3-(1naphthyloxy)propan-2ol
(2S)-1-[4-(4chlorophenyl)piperazin1-yl]-3-(1naphthyloxy)propan-2ol
(2S)-1-(1naphthyloxy)-3-[4-(ptolyl)piperazin-1yl]propan-2-ol

15

16

2-[2-(5,6-dimethyl-1Hbenzoimidazol-2yl)vinyl]-5,6-dimethyl1H-benzoimidazole
2-(2-fluorophenyl)-6phenyl-3-propyl-2H5,6,7-trihydroindazol-4one
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17

ZINC01722585
136513
22600-28-8
410.374
furan

DIBENZOYLFURAN
DERIV

18

ZINC05201470
178873
67194-28-9
268.263
furan

19

ZINC01735469
201631
NO CAS
436.441
thiophene

3-[3-[(2oxotetrahydrofuran-3ylidene)methoxy]propo
xymethylene]tetrahydro
furan-2-one
4-[[4-amino-3-cyano-5(3-nitrobenzoyl)-2thienyl]amino]benzoicacid-ethyl-ester

20

ZINC00031410
203837
NO CAS
267.283
Alkylurea/ oxazole
ZINC05580600
215718
NO CAS
401.277
benzamidine
ZINC01556940
252359
NO CAS
343.834
Piperazine/
triazole

N-(5-methyl-3isoxazolyl)-N'-1naphthylurea

23

ZINC01568966
309892
407.873
thiophene

4-amino-5-(5chlorobenzofuran-2carbonyl)-2-(mtoluidino)thiophene-3carbonitrile

24

ZINC05641037
310347
NO CAS
348.849
thiazole
ZINC00138096
310365
NO CAS
332.871
thiazole

2-[4-(4-chlorophenyl)1,3-thiazol-2-yl]-5phenylpenta-2,4dienenitrile

21

22

25

3-bromo-N-[(5-hydroxy1-naphthyl)aminosulfanyl-methylene]benzamide
2-(4-chlorophenyl)-5methyl-7-(4-methyl-1piperazinyl)[1,2,4]triazo
lo[1,5-a]pyrimidine

2-({[2-(4-chlorophenyl)1,3-thiazol-4yl]methyl}thio)aniline
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26

ZINC01045530
31945
NO CAS
367.422
thiazine

2-(4-hydroxy-3methoxyphenyl)-4-oxo6-(3-toluidino)-3,4dihydro-2H-1,3thiazine-5-carbonitrile

27

ZINC01572309
319990
NO CAS
474.558
thiazole

3-(1,3-benzothiazol-2yl)-1-(5-{[(1,3benzothiazol-2yl)carbamoyl]amino}-2methylphenyl)urea

28

ZINC00640726
319994
NO CAS
362.385
Alkylurea/ pyridine

3-(2-methyl-5-{[(pyridin3yl)carbamoyl]amino}ph
enyl)-1-(pyridin-3yl)urea

29

ZINC01574615
329249
NO CAS
348.764
Alkylurea/ thiazole

3-(1,3-benzothiazol-2yl)-1-(4-chloro-3nitrophenyl)urea

30

ZINC05665089
329250
NO CAS
348.764
Alkylurea/ thiazole

1-benzothiazol-2-yl-3(2-chloro-4-nitrophenyl)-urea

31

ZINC01574620
329255
NO CAS
329.44
Alkylurea/ thiazole

1-(4-methyl-1,3benzothiazol-2-yl)-3-[3(methylthio)phenyl]urea
1-(4-methyl-1,3benzothiazol-2-yl)-3-[3(methylthio)phenyl]urea

32

ZINC01586128
366801
NO CAS
332.828
Alkylurea/pyrazole

N-(1-tert-butyl-3cyclopropyl-1H-pyrazol5-yl)-N'-(4chlorophenyl)urea;
nsc366801 N-(1-tertbutyl-3-cyclopropyl1H…

75
33

ZINC00395036
375982
20575-74-0
344.451
Alkylurea /
piperdine

N-[2-methyl-5(piperidin-1ylcarbonylamino)phenyl
]piperidine-1carboxamide

